SUTENT is used to treat GIST (gastrointestinal stromal tumor). This is a rare cancer of the stomach, bowel, or esophagus. SUTENT is used when the medicine Gleevec® (imatinib mesylate) did not stop the cancer from growing or when you cannot take Gleevec.
Gleevec is a registered trademark of Novartis AG.

First Resource offers services that can help you access Pfizer medicines. Enrollment
is easy. A simple phone call can start the process. If you need to take a Pfizer
cancer medicine, First Resource offers these services:*
 |
- Reimbursement Support Services—A First Resource counselor can help you
understand your coverage and reimbursement options. One of the ways the
counselor can help includes benefit verification, in which your counselor will
review your insurance benefits to see how you are covered for SUTENT. Your
counselor will research and verify benefits and explain coverage options and
policies, as well as investigate and explain the prior authorization process, if
required for SUTENT
- Alternate Funding Assistance—First Resource can help you find other sources
of funding (if available) if you need them. These may include state
pharmaceutical assistance programs (SPAPs), Medicaid, Medicare Part D,
low-income subsidies, and charitable foundations
- Appeals Process Information—First Resource will investigate and explain
the appeals process if your insurance company underpays a claim or denies
coverage
|
Medicines available through First Resource include SUTENT. For a complete list,
please see
www.PfizerHelpfulAnswers.com.
 |
In order to view PDF documents, you must have Adobe® Reader®
installed on your computer. If you do not have Adobe Reader, download it from the
Adobe Web site.
|
Note that the Adobe Web site is neither owned nor controlled by Pfizer. Pfizer is
not responsible for the content or services on that site.
Adobe, the Adobe logo, and Reader are registered trademarks of Adobe Systems Incorporated
in the United States and/or other countries.